CAI International, Inc. operates as a transportation finance company in the United States, Switzerland, France, Korea, Singapore, rest of Asia, rest of Europe, and internationally. The company leases, re-leases, and disposes equipment; and contracts for the repair, repositioning, and storage of equipment. It leases its container equipment to lessees under long-term, short-term, and finance leases. The company also sells containers; and manages equipment for to third-party investors, as well as sells used containers. As of December 31, 2020, it had a container fleet comprised 1,798,520 cost equivalent units. The company was formerly known as Container Applications International, Inc. and changed its name to CAI International, Inc. in February 2007. CAI International, Inc. was incorporated in 1989 and is headquartered in San Francisco, California.
IPO Year: 2025
Exchange: NYSE
Website: capps.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2026 | Peer Perform | Wolfe Research | |
| 4/13/2026 | $28.00 | Buy | Jefferies |
| 4/10/2026 | $21.00 | Neutral | Piper Sandler |
| 4/1/2026 | $27.00 | Buy | Goldman |
| 2/17/2026 | $26.00 | Outperform | Robert W. Baird |
| 12/2/2025 | $28.00 | Hold | Canaccord Genuity |
| 7/14/2025 | $31.00 | Buy | BofA Securities |
| 7/14/2025 | $31.00 | Overweight | Analyst |
| 7/14/2025 | $32.00 | Buy | Guggenheim |
| 7/14/2025 | $33.00 | Outperform | Evercore ISI |
Fastest customizable press release news feed in the world
IRVING, Texas, July 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading TechBio company, today announced it will report second quarter 2026 financial results on Wednesday, August 5, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.Webcast Details:Date: Wednesday, August 5, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/ff8xb4qsA replay of the webcast will be available shortly after the conclusion of the call on the Investor Relations section of the Caris Life Sciences website at CarisLifeSciences.com.About
IRVING, Texas, July 14, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced it will offer in-house PTEN immunohistochemistry (IHC) testing following the recent FDA approval of a biomarker-guided therapy and companion diagnostic assay. This testing is designed to help identify patients with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously known as metastatic hormone-sensitive prostate cancer) who are eligible for the newly approved biomarker-guided therapy, representing a significant advancement in precision oncology fo
Ultra-deep Whole Genome and Whole Transcriptome sequencing combined with sophisticated AI algorithmsdelivers superior performance to existing cancer detection technologiesIRVING, Texas, July 1, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the commercial launch of Caris Detect™, a groundbreaking multi-cancer early detection blood test designed to uncover cancer signals at earlier, more treatable stages. Caris Detect is engineered to push the boundaries of what is possible in early cancer detection. Using ultra
IRVING, Texas, June 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced the dual listing of its common stock on NYSE Texas effective on June 17, 2026, further expanding its presence in the public markets. Caris' shares will continue to be listed and trade on its primary exchange, the NASDAQ, with a dual listing on the NYSE Texas under the same CAI ticker symbol, expected to provide additional exposure to investors, particularly within Texas and the broader U.S. market."Establishing a dual listing on NYSE Texas re
IRVING, Texas, June 8, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI) ("Caris" or the "Company"), a leading next-generation AI TechBio company and precision medicine pioneer, today announced that its Board of Directors has authorized a share repurchase program for up to $100 million of the Company's outstanding common stock. Under the repurchase program, the Company may repurchase shares from time to time through open market purchases, in privately negotiated transactions, or by other means, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as ame
Inaugural story spotlights a woman whose presumed stage 4 metastatic breast cancer diagnosis was corrected by Caris GPSai, an AI-powered tissue-of-origin model, revealing a highly treatable lymphomaIRVING, Texas, May 26, 2026 /PRNewswire/ -- Caris Life Sciences®, Inc. (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today launched "Behind the Diagnosis," a new campaign that spotlights patients whose care has been targeted and personalized by Caris' comprehensive molecular profiling and AI-powered precision medicine. The inaugural story features Erika Rios, who was diagnosed prior to Caris testing, with stage 4 metastatic triple-nega
The Caris Lookback Program identified 13,293 patients potentially eligible for newly approved targeted therapies across 10 tumor types IRVING, Texas, May 15, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the publication of a Caris‑led study in The Oncologist demonstrating the ability of the Caris Lookback Program to proactively identify previously-profiled patients who become eligible for newly approved targeted therapies. Molecular profiling reports from most
AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: For decades, reliably identifying drug and alcohol impairment has been a persistent problem across industries, from traffic enforcement and occupational safety to clinical medicine and public health. Conventional tools such as breathalyzers, blood draws and urine tests are hampered by their intrusiveness, slow turnaround times or inability to capture real-time impairment, especially when multiple substances are involved. As substance-use patterns shift and the broader societal costs of intoxication continue to mount, the pressure to develop faster, less invasive, and more scalable detection methods is intensifyi
Targeted gene panels miscalculate tumor mutational burden in 10–15% of patients, directly resulting in incorrect pembrolizumab eligibility determinationIRVING, Texas, May 11, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Cancer Immunology, Immunotherapy demonstrating that measuring tumor mutational burden (TMB) using ultra-deep Whole Exome Sequencing (WES) provides superior prediction of pembrolizumab immunotherapy benefit compared to estimates of TMB from targeted gene panels. TMB is a pan-tumor biomarker used to determine patients' eligibility for pembrolizumab.
IRVING, Texas, May 8, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced that it has submitted an application to the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP), administered through the Wadsworth Center, seeking authorization to perform Caris Assure®, its blood‑based molecular profiling test, on specimens originating from New York State. Caris Assure is a blood‑based molecular profiling test designed to support comprehe
CERT - Caris Life Sciences, Inc. (0002019410) (Filer)
8-A12B - Caris Life Sciences, Inc. (0002019410) (Filer)
8-K - Caris Life Sciences, Inc. (0002019410) (Filer)
SCHEDULE 13G/A - Caris Life Sciences, Inc. (0002019410) (Subject)
SCHEDULE 13G/A - Caris Life Sciences, Inc. (0002019410) (Subject)
10-Q - Caris Life Sciences, Inc. (0002019410) (Filer)
8-K - Caris Life Sciences, Inc. (0002019410) (Filer)
DEFA14A - Caris Life Sciences, Inc. (0002019410) (Filer)
DEF 14A - Caris Life Sciences, Inc. (0002019410) (Filer)
SCHEDULE 13G/A - Caris Life Sciences, Inc. (0002019410) (Subject)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Wolfe Research resumed coverage of Caris Life Sciences with a rating of Peer Perform
Jefferies initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $28.00
Piper Sandler initiated coverage of Caris Life Sciences with a rating of Neutral and set a new price target of $21.00
Goldman initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $27.00
Robert W. Baird initiated coverage of Caris Life Sciences with a rating of Outperform and set a new price target of $26.00
Canaccord Genuity initiated coverage of Caris Life Sciences with a rating of Hold and set a new price target of $28.00
BofA Securities initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $31.00
Analyst initiated coverage of Caris Life Sciences with a rating of Overweight and set a new price target of $31.00
Guggenheim initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $32.00
Evercore ISI initiated coverage of Caris Life Sciences with a rating of Outperform and set a new price target of $33.00
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
This live feed shows all institutional transactions in real time.
SC 13G/A - CAI International, Inc. (0001388430) (Subject)
SC 13G - CAI International, Inc. (0001388430) (Subject)
SC 13G - CAI International, Inc. (0001388430) (Subject)
SC 13G - CAI International, Inc. (0001388430) (Subject)
SC 13G/A - CAI International, Inc. (0001388430) (Subject)
SC 13D - CAI International, Inc. (0001388430) (Subject)
SC 13D/A - CAI International, Inc. (0001388430) (Subject)
SC 13D/A - CAI International, Inc. (0001388430) (Subject)
SC 13G/A - CAI International, Inc. (0001388430) (Subject)
SC 13G/A - CAI International, Inc. (0001388430) (Subject)
Live finance-specific insights
IRVING, Texas, July 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading TechBio company, today announced it will report second quarter 2026 financial results on Wednesday, August 5, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.Webcast Details:Date: Wednesday, August 5, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/ff8xb4qsA replay of the webcast will be available shortly after the conclusion of the call on the Investor Relations section of the Caris Life Sciences website at CarisLifeSciences.com.About
Revenue growth of 79% driven by strong performance in molecular profiling servicesIRVING, Texas, May 7, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (NASDAQ:CAI), a leading, patient centric, next-generation AI TechBio company and precision medicine pioneer, today reported financial results for the quarter ended March 31, 2026. First Quarter 2026 Financial HighlightsReported total revenue of $216.2 million, an increase of 79% over the corresponding prior year period.Completed approximately 52,800 clinical therapy selection cases, an increase of approximately 15% over the corres
IRVING, Texas, April 20, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.Webcast Details:Date: Thursday, May 7, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/6iwr2xf8/A replay of the webcast will be available shortly after the conclusion
IRVING, Texas, Feb. 9, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Thursday, February 26, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/49czfgs4 A replay of th
IRVING, Texas, Oct. 23, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report third quarter 2025 financial results on Wednesday, November 5, 2025. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Wednesday, November 5, 2025Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/uwjxydsa A replay of the webcast will
IRVING, Texas, July 23, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report second quarter 2025 financial results on Tuesday, August 12, 2025. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Tuesday, August 12, 2025Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/hfsyg967 A replay of the webcast will be a
CAI International, Inc. (NYSE:CAI) ("CAI" or the "Company"), one of the world's leading transportation finance companies, announced today that CAI's Board of Directors declared a cash dividend of $0.30 per common share payable on September 27, 2021 to shareholders of record as of September 10, 2021. About CAI International, Inc. CAI is one of the world's leading transportation finance companies. As of June 30, 2021, CAI operated a worldwide fleet of approximately 1.9 million CEUs of containers. CAI operates through 13 offices located in 12 countries including the United States. Additional Information and Where to Find It This communication relates to the proposed merger involving the Co
Purchase Price of $56.00 per Common Share in Cash CAI International, Inc. (NYSE:CAI) ("CAI" or the "Company"), one of the world's leading transportation finance companies, announced today that it has entered into a definitive agreement to be acquired by Mitsubishi HC Capital Inc. ("MHC"). Under the terms of the merger agreement with MHC (the "Merger Agreement"), MHC will acquire all of CAI's outstanding and fully diluted common stock in an all-cash transaction for $56.00 per share, which represents a total equity value of approximately $1.1 billion, consisting of $104 million (par value) of preferred stock and $986 million of common stock equity value, assuming a fully-diluted share count
CAI International, Inc. ("CAI" or the "Company") (NYSE:CAI), one of the world's leading transportation finance companies, today reported results for the first quarter of 2021. Highlights Net income from continuing operations attributable to CAI common stockholders for the first quarter of 2021 was $32.5 million, or $1.85 per fully diluted share. Return on common equity on adjusted net income from continuing operations1 was 21.3% in the first quarter of 2021. Total leasing revenue for the first quarter of 2021 was $80.8 million, compared to $69.1 million in the first quarter of 2020. CAI's Board of Directors declared a cash dividend of $0.30 per common share payable on June 25, 2021
SAN FRANCISCO--(BUSINESS WIRE)--CAI International, Inc. (“CAI” or the “Company”) (NYSE: CAI), one of the world’s leading transportation finance companies, today reported results for the fourth quarter and full year of 2020. Highlights Net income from continuing operations attributable to CAI common stockholders for the fourth quarter of 2020 was a record $32.5 million, or $1.81 per fully diluted share. Adjusted net income from continuing operations attributable to CAI common stockholders1 for the fourth quarter of 2020 was also a record at $31.6 million, or $1.76 per fully diluted share. Return on equity on adjusted net income from continuing operations1 was 21.2% in the fo